Cannabis as medicine for chronic pain

About a quarter of people in Germany suffer from chronic pain. Non-drug and drug pain therapy may not be sufficient in some cases to achieve effective pain relief. Effective complementary measures such as medical cannabis therapy are then required.

Since the knowledge on the use of cannabis for medical purposes has been improved in recent years by a large number of clinical studies, the administration of cannabis-containing medicines can be useful for patients who do not experience sufficient pain relief under standard therapy. Before we delve deeper into this topic, however, we will briefly explain what forms of pain there are and what therapeutic options are available.

What are the different types of pain?

The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”.

Pain medicine distinguishes between the following types of pain, among others:

Physiological nociceptor painThis pain is caused by the excitation of nociceptors that react to different influences (e.g. cold, heat, pressure) and transmit the information to the central nervous system.
Pathological nociceptor painWhen tissue is damaged (e.g. bruising), inflammatory cells are mobilised, which then interfere with the affected area, making it more sensitive than normal (e.g. sunburn).
Neuropathic painNeuropathic pain (nerve pain) occurs when the nerve fibres are injured, such as in a herniated disc. It can be seizure-like, shooting, burning and dull.
Reflective painThis type of pain is triggered by a disturbed motor function. The pain receptors are excited by muscle tension. The pain then in turn increases the muscle tension, creating a cycle of muscle pain and muscle tension.
Muscle/soft tissue painSoft tissue pain is caused, for example, by the disease fibromyalgia. The pain is usually limited to certain areas of the body..
Attack painAttack pain occurs, for example, with headaches (tension headaches or migraines).
Psychogenic painIn this pain syndrome, no physical causes can be found. The symptoms are based on psychological processes (mental stress, psychological problems or illnesses).

More information on the different forms of pain can be found here. 

What is the difference between acute and chronic pain?

Acute pain occurs, for example, during an injury and is a warning signal from the body. Normally, it is limited to the place where it originates. When the cause has been eliminated, for example when the injury has healed, the pain disappears by itself.

With chronic pain, the function as a warning signal is lost. This means that the pain symptoms persist despite the healed cause. Doctors speak of chronic pain when it has persisted for at least three months and significantly impairs the patient’s quality of life. The former pain symptoms then develop into a separate disease.

Therapy of chronic pain

Since chronic pain syndrome is a complex disease, treatment is often not easy. A multimodal therapy, i.e. a combination of different non-drug therapies that are individually adapted to the patient, promises the greatest success. This can include the following treatment methods, for example:

  • Physiotherapy: Various physical therapy methods, such as physiotherapy, exercise therapy, heat or cold applications, can alleviate pain.
  • Invasive therapies: Depending on the type of pain, invasive procedures such as injections or nerve stimulation can be helpful.
  • Complementary procedures: Complementary to conventional medical treatment, naturopathic treatments, homeopathic remedies or traditional Chinese medicine (TCM) can also reduce pain conditions. Other possible procedures include acupuncture, acupressure and osteopathy.
  • Psychological therapy: Psychosocial and psychological factors play a significant role in the development and chronification of pain. Many patients suffer from depressive moods or even develop depression, which intensifies the pain symptoms. In such cases, cognitive-behavioural therapy may be indicated.

Treatment with medication

In addition to the previously mentioned therapy methods, medications are also used for chronic pain syndrome. For short-term use, patients are often given classic painkillers, such as paracetamol, acetylsalicylic acid (ASA), naproxen, ibuprofen or diclofenac. Since these drugs can affect the gastrointestinal mucosa and blood pressure, long-term use should be carefully considered.

If patients suffer from neuropathic pain, doctors often prescribe anticonvulsant drugs such as lamotrigine, topiramate or gabapentin. Although these are mainly used in the treatment of epilepsy, it is known that the active substances can positively influence certain pain processes in the body. Topiramate, for example, is used for migraine prophylaxis. However, these drugs are not free of side effects; symptoms such as ataxia, fatigue and dizziness can occur.

In the context of pain therapy, many doctors also prescribe antidepressants (tricyclic antidepressants such as amitriptyline or serotonin and noradrenaline reuptake inhibitors), as they can positively influence pain processing in low doses.

Use of opioids

For very severe chronic pain, doctors prescribe opioids. These are divided into weaker-acting and strong-acting drugs. The former include painkillers like tilidine or dihydrocodeine. Stronger-acting drugs are fentanyl, buprenorphine and oxycodone.

Opioids can cause unwanted side effects such as nausea, vomiting, dry mouth, constipation, loss of appetite, headaches as well as psychiatric disorders. In order to alleviate these symptoms, those affected are then usually given further medication.

In addition, there is an increased risk of dependence with opioids. In addition, patients build up an opioid tolerance relatively quickly, so that the dose has to be increased more and more to achieve a sufficient effect.

Interesting information on pain therapy is also provided by the German Society for Pain Medicine

Mechanism of action of medicinal cannabis for pain

The cannabinoids of the cannabis plant such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have analgesic and anti-inflammatory properties. They exert their effect by interacting with the endocannabinoid system and its cannabinoid receptors in the body. It is now known that the endocannabinoid system plays an important role in various physiological processes such as pain management.

For example, when an injury occurs, the body produces the messenger substance prostaglandin, which is produced by the enzyme cyclooxygenase (COX). The prostaglandin then binds to the pain receptors so that the brain perceives the pain. Classical drugs (non-opioid painkillers such as ibuprofen) block the COX enzyme. As a result, the prostaglandin is no longer produced.

Opioids have a different mechanism of action. They bind to the opioid receptors in the central nervous system (brain and spinal cord) and in the peripheral nervous system (nerve cells outside the brain and spinal cord).

Cannabinoids also act in the spinal cord. However, opioids paralyse the entire pain transmission, whereas cannabinoids “only” slow down the transmission of pain.

Before a pain impulse reaches consciousness, the spinal cord can weaken or intensify it. This effect is called gate control. Various studies have shown that cannabinoids are able to change the gate control or weaken the pain impulse (1).

Cannabinoids influence the perception of pain

Various studies suggest that cannabinoids do not reduce pain intensity but make the discomfort more bearable. For example, researcher Martin De Vita of Syracuse University in the US stated in his meta-study that THC in particular was associated with moderate increases in pain tolerance and pain threshold (3). There was no reduction in pain intensity shown. However, pain was perceived as less unpleasant.

He further explained that the present study had focused on the use of THC. It was unclear whether other cannabinoids would lead to different results.

Cannabis as medicine is particularly effective for neuropathic pain

Medical cannabis shows a positive effect especially in chronic neuropathic pain and pain in the context of multiple sclerosis (4). In a parallel group study involving 50 patients with HIV-associated neuropathic pain, it was shown that pain symptoms were significantly reduced after smoking cannabis. 

The same result was obtained in a cross-over study in which patients received dronabinol for MS-related pain. In addition, smaller controlled studies showed that medical cannabis can also be effective for chronic pain of other causes such as fibromyalgia, rheumatism and tumour pain.

Conclusion

Chronic pain symptomatology is one of the well-established healing indications of medicinal cannabis. Various placebo-controlled studies have already been able to prove the corresponding effect.

Non-opioid drugs as well as opioids in particular can cause severe side effects. Studies suggest that the combination of pharmaceuticals and cannabis-based medicines can not only mitigate the side effects, but that it is possible for patients to reduce the dose of pain medication and opioids. Another advantage is that patients do not develop a tolerance to the use of medical cannabis as they do with opioids. 

Accordingly, for many patients, medical cannabis can be an important component in the overall structure of pain therapy to achieve pain relief and improve quality of life.

(1) Starowicz K, Finn DP. Cannabinoids and Pain: Sites and Mechanisms of Action. Adv Pharmacol. 2017;80:437-475. doi: 10.1016/bs.apha.2017.05.003. Epub 2017 Jun 20. PMID: 28826543

(2) Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 2016 Dec;32(12):1036-1043. doi: 10.1097/AJP.0000000000000364. PMID: 26889611

(3) De Vita MJ, Moskal D, Maisto SA, Ansell EB. Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2018 Nov 1;75(11):1118-1127. doi: 10.1001/jamapsychiatry.2018.2503. PMID: 30422266; PMCID: PMC6248100

(4) Grotenhermen F, Müller-Vahl K, The therapeutisch potential of cannabis and cannabinoids, Dtsch Arztebl Int 2012; 109(29-30): 495-501; DOI: 10.3238/ärztebl.2012.0495

About Alexandra

Alexandra Latour verfügt über langjähre Erfahrungen als Autorin im medizinischen Bereich. Ab dem Jahr 2017 hat sie sich als Medical Writer auf das Thema Cannabis als Medizin spezialisiert und war für Leafly Deutschland tätig.